Pascal Piedbois, MD, PhD joins One2Treat as Chief Medical Officer

‍

In this new role, Dr. Piedbois will ensure the One2Treat suite of offerings are developed and delivered with the requirements of both patients, and our customer's clinical teams, front and center. 

One2Treat’s innovative approach, driven by its Founder Marc Buyse, aims to reduce trial sample sizes and accelerate patient access to new treatments. This is achieved by incorporating multiple clinical outcomes that matter to the patient as early as the study design through robust statistical methodologies. Dr. Pascal Piedbois will be a key driver in this endeavor.

Dr. Pascal Piedbois, Prof. of Medical Oncology, brings over 30 years of clinical development experience in both academia and industry, holding positions including Head of Medical Oncology at Paris University, General Director of the Comprehensive Cancer Center of Alsace Region, and several leadership roles in the pharmaceutical industry, including Vice President, Head of Global Oncology and Infectious Diseases at AstraZeneca, Senior Vice President, Medical Head Major Markets at Bristol Myers Squibb and General Manager at Boehringer-Ingelheim Belgium. 

“Pascal’s extensive medical experience will address one of the most strategic challenges in the biopharma industry today: incorporating multiple patient-relevant outcomes into a single holistic treatment assessment," said Sebastien Coppe, CEO of One2Treat. "Pascal’s deep industry knowledge will ensure that our innovative solutions bring clinically meaningful transformations in the way we design clinical trials and handle key market-access questions, such as benefit-risk analyses. In today’s clinical studies, focusing on one or two primary endpoints often leads to underutilization of valuable data and fails to capture the holistic impact of treatments on patients.”

Dr. Pascal Piedbois adds: “There is a huge opportunity to involve patients, sponsors, regulatory agencies, and payers early in the clinical trial design process. By aligning on their specific needs and prespecifying the primary endpoint of the registration study, we can run more efficient trials and bring new treatments to market faster. This approach will ensure that clinical trials are more reflective of what truly matters to patients, including quality of life for instance.” 

Marc Buyse, Founder of One2Treat, highlights the need for a more patient-centric approach in clinical research: “I am delighted that Pascal, with whom I have had a long and very fruitful collaboration, joins One2Treat today. His medical expertise will speed up the implementation of this multi-dimensional approach, ensuring our message resonates with medical leaders.” 

Dr. Pascal Piedbois concludes: “One2Treat’s innovative approach not only enhances trial design and analysis but also facilitates a more transparent and efficient transition from drug development to market access. Using a rigorous, quantitative method to analyze overall treatment effects allows us to connect clinical research and health technology (HTA) assessment seamlessly, providing a comprehensive benefit-risk assessment based on what matters most to patients.” 

As One2Treat emerges to disrupt the status quo in both clinical research and HTA/market access, its vision transcends traditional stakeholders to include clinicians and patients themselves. Through its dedicated software solution, One2Treat aims to empower individuals to voice their treatment preferences and access personalized care tailored to their unique specific needs.  

https://www.prnewswire.com/news-releases/pascal-piedbois-md-phd-joins-one2treat-as-chief-medical-officer-to-advance-patient-centric-innovation-in-clinical-trial-design-and-market-access-302192051.html

‍

‍